Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
Immunovia (IMMNOV: Nasdaq Stockholm) presented results from its model development study for a next-generation pancreatic cancer detection test at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer. The study, involving 623 patient samples, demonstrated the test's superior performance with 85% sensitivity and 98% specificity. Notably, the test's sensitivity surpassed that of CA19-9, a common pancreatic cancer biomarker, by 20 percentage points.
The presentation detailed the biomarker selection process, algorithm construction, and test performance. Immunovia's VP of Clinical and Medical Affairs, Norma Palma PhD, emphasized the importance of scientific review and data dissemination for driving adoption of the test, which is slated for launch next year.
Immunovia (IMMNOV: Nasdaq Stockholm) ha presentato i risultati del suo studio di sviluppo del modello per un test di rilevamento del cancro pancreatico di nuova generazione durante la Conferenza Speciale AACR sulla Ricerca sul Cancro: Progressi nel Cancro Pancreatico. Lo studio, che ha coinvolto 623 campioni di pazienti, ha dimostrato la superiorità delle prestazioni del test con una sensibilità del 85% e una specificità del 98%. In particolare, la sensibilità del test ha superato quella del CA19-9, un biomarker comune per il cancro pancreatico, di 20 punti percentuali.
La presentazione ha dettagliato il processo di selezione dei biomarker, la costruzione dell'algoritmo e le prestazioni del test. Norma Palma PhD, VP delle Affari Clinici e Medici di Immunovia, ha sottolineato l'importanza della revisione scientifica e della diffusione dei dati per promuovere l'adozione del test, previsto per il lancio il prossimo anno.
Immunovia (IMMNOV: Nasdaq Stockholm) presentó los resultados de su estudio de desarrollo de modelo para una prueba de detección de cáncer de páncreas de nueva generación en la Conferencia Especial AACR sobre Investigación del Cáncer: Avances en el Cáncer de Páncreas. El estudio, que involucró 623 muestras de pacientes, demostró el rendimiento superior de la prueba con una sensibilidad del 85% y una especificidad del 98%. Notablemente, la sensibilidad de la prueba superó a la del CA19-9, un biomarcador común para el cáncer de páncreas, en 20 puntos porcentuales.
La presentación detalló el proceso de selección de biomarcadores, la construcción del algoritmo y el rendimiento de la prueba. Norma Palma PhD, VP de Asuntos Clínicos y Médicos de Immunovia, enfatizó la importancia de la revisión científica y la difusión de datos para impulsar la adopción de la prueba, que se prevé lanzar el próximo año.
Immunovia (IMMNOV: 나스닥 스톡홀름)는 AACR 특별 회의에서 차세대 췌장암 검출 테스트의 모델 개발 연구 결과를 발표했습니다. 이 연구는 623명의 환자 샘플을 포함하고 있으며, 테스트의 뛰어난 성능을 보여주었고 85% 민감도와 98% 특이도를 기록했습니다. 특히, 테스트의 민감도는 일반적인 췌장암 바이오마커인 CA19-9보다 20퍼센트 포인트 더 높았습니다.
발표에서는 바이오마커 선택 프로세스, 알고리즘 구축 및 테스트 성능에 대해 자세히 설명했습니다. Immunovia의 임상 및 의료 담당 부사장인 Norma Palma 박사는 테스트의 채택을 촉진하기 위한 과학적 검토와 데이터 배포의 중요성을 강조했으며, 해당 테스트는 내년 출시될 예정입니다.
Immunovia (IMMNOV: Nasdaq Stockholm) a présenté les résultats de son étude de développement de modèle pour un test de détection du cancer du pancréas de nouvelle génération lors de la Conférence Spéciale AACR sur la Recherche sur le Cancer : Avancées dans le Cancer du Pancréas. L'étude, impliquant 623 échantillons de patients, a démontré les performances supérieures du test avec une sensibilité de 85 % et une spécificité de 98 %. Notamment, la sensibilité du test a dépassé celle du CA19-9, un biomarqueur courant du cancer du pancréas, de 20 points de pourcentage.
La présentation a détaillé le processus de sélection des biomarqueurs, la construction de l'algorithme et les performances du test. Norma Palma, PhD, VP des affaires cliniques et médicales chez Immunovia, a souligné l'importance de l'examen scientifique et de la diffusion des données pour favoriser l'adoption du test, prévu pour être lancé l'année prochaine.
Immunovia (IMMNOV: Nasdaq Stockholm) hat die Ergebnisse seiner Modellentwicklungsstudie für einen Test zur Erkennung von Bauchspeicheldrüsenkrebs der nächsten Generation auf der AACR-Sonderkonferenz zur Krebsforschung: Fortschritte bei Bauchspeicheldrüsenkrebs vorgestellt. Die Studie, die 623 Patient:innenproben umfasste, zeigte die überlegene Leistung des Tests mit einer Empfindlichkeit von 85% und einer Spezifität von 98%. Bemerkenswerterweise übertraf die Empfindlichkeit des Tests die des CA19-9, eines gängigen Biomarkers für Bauchspeicheldrüsenkrebs, um 20 Prozentpunkte.
Die Präsentation erläuterte den Prozess der Biomarker-Auswahl, den Aufbau des Algorithmus und die Testleistung. Norma Palma, PhD, VP für klinische und medizinische Angelegenheiten bei Immunovia, betonte die Bedeutung der wissenschaftlichen Überprüfung und der Datenverbreitung zur Förderung der Akzeptanz des Tests, der für die Markteinführung im nächsten Jahr geplant ist.
- Immunovia's new pancreatic cancer test showed 85% sensitivity and 98% specificity in a 623-patient sample study
- The test's sensitivity exceeded that of CA19-9, a common pancreatic cancer biomarker, by 20 percentage points
- Presentation at a prestigious AACR conference may increase visibility and credibility for Immunovia's technology
- The company estimates a potential market of 1.8 million high-risk individuals in the USA who could benefit from annual testing
- The test is still in development and not yet commercially available
- Actual market adoption and revenue generation remain uncertain
The presentation of Immunovia's model development study results at the AACR conference is a significant step forward in pancreatic cancer diagnostics. The 85% sensitivity and 98% specificity of their next-generation test are impressive figures, especially for early-stage detection. This 20 percentage point improvement over CA19-9 could be a game-changer in early diagnosis.
However, it's important to note that these results are from a controlled study with 623 samples. Real-world performance may vary. The true test will be in prospective clinical trials and eventual clinical implementation. The company's focus on rigorous scientific review is commendable, but investors should watch for peer-reviewed publications and independent validation of these results.
Immunovia's focus on the US market is strategically sound, given its estimate of 1.8 million high-risk individuals who could benefit from annual testing. This represents a substantial market opportunity. However, market penetration will depend on factors like cost-effectiveness, insurance coverage and physician adoption.
The company's collaboration with healthcare providers and patient advocacy groups is important for market acceptance. Investors should monitor progress in these partnerships and any advancements in reimbursement discussions. While the potential is significant, the path from promising study results to commercial success in diagnostics can be long and uncertain, especially in a field as challenging as pancreatic cancer detection.
Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. The company disclosed its method for selecting the biomarkers that comprise the test, the construction of the test algorithm, and the test's performance and stability. In the study of 623 patient samples, the test demonstrated superior performance, with sensitivity of
The conference is being hosted by the American Association for Cancer Research (AACR) in
"We are grateful to have been selected by the AACR reviewers to present the model-development-study results at this inspiring conference of pancreatic cancer advances. Rigorous scientific review and dissemination of our data will be critical for driving adoption of our next-generation test following its launch next year," said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
+46 70 911 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-presents-data-from-model-development-study-at-2024-aacr-advances-in-pancreatic-cancer-medical-conference-302249247.html
SOURCE Immunovia AB
FAQ
What were the key results of Immunovia's pancreatic cancer test study presented at the 2024 AACR conference?
When is Immunovia (IMMNOV) planning to launch its new pancreatic cancer detection test?
How large is the potential market for Immunovia's pancreatic cancer test in the USA?
What is the focus of Immunovia's (IMMNOV) diagnostic technology?
